Navigation Links
PharmAthene Reports Year-End 2007 Financial Results
Date:3/31/2008

able - 11,768,089

Current portion of long term debt 4,000,000 -

Total current liabilities 8,996,550 14,194,226

Warrants to purchase Series C convertible

redeemable preferred stock - 2,423,370

Other long-term liabilities 374,040 -

Long term debt 16,668,458 -

Total liabilities 26,039,048 16,617,596

Minority interest -- Series C convertible

redeemable preferred stock of PharmAthene

Canada, Inc. $0.001 par value; unlimited

shares authorized; 2,591,654 issued and

outstanding; liquidation preference in the

aggregate of $2,719,178 - 2,545,785

Series A convertible redeemable preferred

stock; $0.001 par value; 16,442,000 shares

authorized, issued and outstanding; liquidation

preference in the aggregate of $19,355,388 - 19,130,915

Series B convertible redeemable preferred

stock; $0.001 par value; 65,768,001 shares

authorized; 30,448,147 issued and outstanding;

liquidation preference in the aggregate of

$33,010,797 - 31,780,064

Series C convertible redeemable preferred

stock; $0.001 par value; 22,799,574 shares

authorized; 14,946,479 issued and outstanding;

liquidation preference in the aggregate of

$15,681,930 - 14,480,946

Stockholders' deficit:

Common stock, $0.0001 par value;

100,000,000 shares authorized; 22,138,723

and 22,087,121 shares issued and

outstanding; respectively at December 31,

2007 and 621,281 shares issued and

outstanding at Decembe
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... Arkansas (PRWEB) December 18, 2014 ... to locate its pilot production facility and future ... develop and produce innovative new materials that safely ... chosen not only because of its historic, strong ... leaders’ efforts to attract leading edge, technology-based companies ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... WALTHAM, Mass. , May 24 Repligen ... of Orphan Products Development of the Food and Drug Administration ... histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ... of marketing exclusivity in the United States if ...
... 24 MO BIO Laboratories, Inc., the leader ... the launch of a groundbreaking new product, PowerLyzer™ 24 ... homogenization and lysis of any biological sample.  The PowerLyzer™ ... analysis faster, minimize cross-contamination, and maintain sample integrity. ...
... CLEVELAND, Ohio , May 24, 2010 Simbionix ... medical professionals and the healthcare industry, is launching,two new hands-on training systems- ... revealed for the first time at,the AUA annual meeting in San ... , ...
Cached Biology Technology:Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for the first time that coenzyme Q10 offsets the cellular ... drugs - an increased risk of adult-onset diabetes. Statins ... world, able to reduce LDL, or "bad" cholesterol levels, and ... their role in raising the risk of diabetes has only ...
... 10, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... become a fully reporting public company with the Securities ... many highlights of the filing is a licensing agreement ... PVM International, Inc., has towards the company,s shareholders. The ...
... 2013, New York, NY A dozen Ludwig scientists ... basic and clinical cancer research at this week,s American ... in immunotherapy and epigenetics led the program with important ... "With new immunotherapy agents available to help ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Medbox Files Form 10 with SEC 2Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR 2